SUCLA2 gene is frequently involved in the deletion of RB1 gene region, which occurs in 10 – 30 % of advanced prostate cancers. SUCLA2 deletion gives rise to a metabolic vulnerability. By screening chemical compounds, thymoquinone appeared to selectively kill SUCLA2-deficeint prostate cancer cells.
Kanazawa University researchers reported that the SUCLA2 gene is frequently involved in the deletion of the tumor suppressor gene RB1 in advanced prostate cancer. RB1 deletion makes cells resistant to hormone therapy but SUCLA2 deletion induces a metabolic weakness. The study showed that thymoquinone selectively killed SUCLA2-deficient prostate cancer cells in vitro and in vivo. The findings highlight a vulnerability of advanced prostate cancer cells that can be targeted by drugs.
The compound thymoquinone (TQ) selectively kills prostate cancer cells at advanced stages, according to a new study published in Oncogene. Led by researchers at Kanazawa University, the study reports that prostate cancer cells with a deletion of the SUCLA2 gene can be therapeutically targeted. SUCLA2-deficient prostate cancers represent a significant fraction of those resistant to hormone therapy or metastatic, and a new therapeutic option for this disease would have immense benefits for patients.
Hormone therapy is often chosen for the treatment of metastatic prostate cancer but nearly half of patients develop resistance to the treatment in as little as 2 years. A mutation in RB1, a tumor suppressor gene that keeps cell growth under control, has been pegged as a particularly strong driver of treatment resistance and predicts poor outcome in patients.
“Mutations in tumor suppressor genes are enough to induce initiation and malignant progression of prostate cancer, but so far we haven’t been able to directly target these mutations with drugs to treat prostate cancer,” says the lead author Susumu Kohno. “We wanted to find a genetic aberration associated with that of a tumor suppressor gene which we could target therapeutically.”
In the genome, SUCLA2 neighbors RB1. An analysis of prostate cancer cells showed that cells with a RB1 deletion were also missing SUCLA2, pairing up the SUCLA2 deletion with the RB1 deletion present in advanced stage prostate cancer. Kohno and colleagues analyzed prostate cancer tissue and found that 11% of cases were missing both SUCLA2 and RB1.
The researchers screened compounds to identify drugs that would selectively kill cells with a SUCLA2 deletion. Out of around 2,000 compounds, TQ emerged as a hit compound. TQ already has known anti-cancer effects and was shown to be safe in a phase I clinical trial. Kohno and colleagues applied the TQ treatment to a mouse model of SUCLA2-deficient prostate cancer and TQ selectively suppressed tumor growth.
“These findings show that TQ treatment could be an effective therapy for treating prostate cancer cells that harbor SUCLA2 deficiency” says the senior author Chiaki Takahashi.
In a search of genetic databases from patients with prostate cancer, the researchers found that the frequency of SUCLA2 loss was almost perfectly aligned with RB1 loss at every disease stage—meaning the SUCLA2 deletion could identify people with prostate cancer needing advanced therapy.
Finding this drug-targetable vulnerability opens a crack in the barrier of treatment resistance for prostate cancer. More work needs to be done to improve efficacy of TQ and identify patients that would benefit from this type of treatment, but the compound provides a promising route for new treatment options for advanced prostate cancer.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Advanced prostate cancer
- APCCC 2022: Biochemical Recurrence After Definitive Radiotherapy of the Prostate – What Are the Local Treatment Options?
(UroToday.com) The 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting included a session on biochemical recurrence, and a presentation by Dr. Jochen Walz discussing local ...
- APCCC 2022: Does “Oligoprogressive” Prostate Cancer Exist as a Distinct Clinically Meaningful Entity and if Yes, How To Treat It?
(UroToday.com) In the session of the 2022 Advanced Prostate Cancer Consensus Conference focusing on the treatment of patients with oligometastatic and oligoprogressive prostate cancer, Dr. Jones ...
- Prostate cancer symptoms: 'Difficulty' starting to pass urine - 'don't delay seeing' GP
and some signal a more advanced stage of the cancer. There are a number of risk factors, such as age, and if you're under 50, your risk of being diagnosed with prostate cancer is very low. Cancer ...
- Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer
The study compared relugolix to leuprolide in over 1,000 men with androgen-sensitive advanced prostate cancer who required at least one year of continuous androgen deprivation therapy. ORGOVYX ® ...
- Arkansas Urology first in state to use advanced prostate cancer diagnostic tool
Arkansas Urology, the state’s largest and most innovative urology practice, is using a new radioactive diagnostic agent, Illuccix, that offers more precise detection of prostate cancer treatment plann ...
Go deeper with Google Headlines on:
Advanced prostate cancer
Go deeper with Bing News on:
- Black Patients Less Likely to Get High-Tech Prostate Cancer Therapy
Black Patients Less Likely to Get High-Tech Prostate Cancer Therapy By By Robert Preidt HealthDay Reporter, HealthDay Reporter MONDAY, May 2, 2022 (HealthDay News) -- Use of a high-tech radiation ...
- Prostate Cancer: What's in a Name?
The authors argue doctors should stop using “cancer” for cases of very low-grade prostate cancer. The article was penned by researchers from various universities and research institutes and a ...
- Doctors suggest new names for low-grade prostate cancer
A cancer diagnosis is scary. Some doctors say it’s time to rename low-grade prostate cancer to eliminate the alarming C-word. Cancer cells develop in nearly all prostates as men age, and most ...
- Signs You Have Prostate Cancer That Worry Doctors
According to the CDC, prostate cancer is the second most common cancer among men in the U.S., after non-melanoma skin cancer. "When prostate cancer is diagnosed before it spreads to other parts of the ...
- Prostate cancer rising in Black community
According to the Prostate Cancer Foundation, prostate cancer has a 99% five-year survival rate for men if the cancer is detected during the early stage. Yet, Black men have a 70% higher rate of ...